NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Lifshitz Law Firm

Nano Nuclear Energy, Inc. (NASDAQ: NNE)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly failed to disclose to investors that: (1) NNE's purported progress toward regulatory approval for the design of its planned micro reactors and fuel fabrication plant was nonexistent; (2) NNE's timelines for commercialization were wildly optimistic, at best, and most likely impossible; (3) the foregoing issues were likely to have a material negative impact on the Company's projected revenues and growth; (4) as a result, the Company's financial position and/or prospects were overstated; and e) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you are an NNE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Extreme Networks, Inc. (NASDAQ: EXTR)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly made false and/or misleading statements and allegedly failed to disclose the following adverse facts pertaining to Extreme's business, operations, and financial condition: (1) that Extreme was suffering from adverse client demand trends as its clients had ordered more product from Extreme than needed in the wake of the COVID-19 pandemic to avoid supply shortages and because of a lack of alternative sourcing options and thereby had cannibalized their purchasing needs; (2) that Extreme was increasingly offsetting these adverse organic demand trends with the fulfillment of backlog orders in a manner that materially exceeded the proportion represented to investors; (3) that, as a result of (1)-(2), Extreme was drawing down its backlog at a much faster rate than represented to investors; (4) that, as a result of (1)-(3), Extreme's backlog was already decreasing and at a much quicker pace than the Company's statements to investors that backlog would only "begin to shrink" in 4Q23 and it would be not until "fiscal ‘26 when it really goes back to normal"; (5) that, as a result of (1)-(4), Extreme's backlog was not on track to continue increasing to $600 million; and (6) that, as a result of (1)-(6) above, the Company had materially misrepresented Extreme's organic demand, revenue growth, and market share gains as the fulfillment of Extreme's backlog masked a decline in organic demand and attendant revenues.

If you are an EXTR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

DexCom, Inc. (NASDAQ: DXCM)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information concerning DexCom's expected revenue for the fiscal year 2024. The Company's statements included, among other things, confidence in DexCom's ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year's gross margins, while scaling customer conversion to the new G7 platform. However, the Company allegedly failed to disclose the true state of DexCom's salesforce; notably, that it was not truly equipped to execute on the Company's perceived growth potential, and that as a result of their purchases of DexCom's common stock investors suffered economic loss.

If you are a DXCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Methode Electronics, Inc. (NYSE: MEI)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly made false and/or misleading statements and/or failed to disclose that: (1) Methode Electronics had lost highly skilled and experienced employees during the COVID-19 pandemic necessary to successfully complete Methode Electronics' transition from its historic low mix, high volume production model to a high mix, low production model at its Monterrey facility; (2) Methode Electronics' attempts to replace its General Motors center console production with more diversified, specialized products for a wider array of vehicle manufacturers and OEMs, in particular in the electric vehicle ("EV") space, had been plagued by production planning deficiencies, inventory shortages, vendor and supplier problems, and, ultimately, botched execution of Methode Electronics' strategic plans; (3) Methode Electronics' manufacturing systems at its critical Monterrey facility suffered from a variety of logistical defects, such as improper system coding, shipping errors, erroneous delivery times, deficient quality control systems, and failures to timely and efficiently procure necessary raw materials; (4) Methode Electronics had fallen substantially behind on the launch of new EV programs out of its Monterrey facility, preventing Methode Electronics from timely receiving revenue from new EV program awards; and (5) as a result, Methode Electronics was not on track to achieve the 2023 diluted earnings-per-share guidance or the 3-year 6% organic sales compound annual growth rate represented to investors and such estimates lacked a reasonable factual basis.

If you are an MEI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com

SOURCE: Lifshitz Law Firm